Work

Lecanemab, an anti-Aβ protofibril antibody: Updated data from a randomized, double-blind phase 2B proof of concept clinical trial and open-label extension in early Alzheimer's disease

Year: 2021

Type: article

Study design: Clinical Trial

Source: Journal of the Neurological Sciences

DOI: 10.1016/j.jns.2021.117847

Authors: Chad Swanson, Shobha Dhadda, Mark Hodgkinson, David Li, Michio Kanekiyo, June Kaplow, Martin Rabe, Helena Heanue-Travers, Robert Gordon, Robert Lai, Lynn Kramer, Larisa Reyderman

Institutions: Eisai (United States), Eisai (United Kingdom)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3207147702

FWCI: 0.474

Cites:

Cited by: 4

Related to: 10